Clinical trials: Hydroxychloroquine
Rheumatic Diseases
Effectiveness of an EHR Interface to Reduce Dosage of Hydroxychloroquine
Hydroxychloroquine (HCQ) is a disease-modifying, anti-rheumatic drug that regulates immune system activity and is typically prescribed to treat rheumatoid arthritis and systemic lupus erythematosus, as well as other immune…
- Trial name
- NCT04310462
- Testing
- New e-prescribing interface
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Pregnancy Related, COVID
Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum
It still unclear how SARS-CoV-2 affects pregnant women and their offspring, as well as which factors may influence obstetrical disease and outcomes, including the timing of maternal viral exposure by gestational age, the effects…
- Conditions
- Pregnancy Related, COVID, Covid-19
- Trial name
- COVID-Preg (NCT04410562)
- Testing
- Hydroxychloroquine
- Where
- 9 sites in Spain
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Barcelona Institute for Global Health
Malaria,Falciparum, Anemia in Children
Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi
This is an individually randomized, controlled, single blind three arm clinical trial of malaria chemoprevention strategies Arm 1: Intermittent preventive treatment with dihydroartemisinin-piperaquine (IPT-DP).
- Trial name
- NCT06083688
- Testing
- Dihydroartemisinin-Piperaquine, Chloroquine, Sulfadoxine-pyrimethamine-amodiaquine
- Where
- Malawi
- Volunteers
- 788 people, healthy volunteers welcome
- Sponsor
- Liverpool School of Tropical Medicine
Covid19, SARS (Severe Acute Respiratory Syndrome)
Safety and Efficacy of Hydroxychloroquine for the Treatment & Prevention of Coronavirus Disease 2019 (COVID-19) Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Coronavirus Disease 2019 (COVID-19) (previously called 2019-nCOV acute respiratory disease) is caused by SARS-CoV-2, a positive-sense single-stranded RNA virus of the coronavirus family.
- Trial name
- NCT04590274
- Testing
- Hydroxychloroquine, Vitamins and Minerals, Azithromycin
- Volunteers
- healthy volunteers welcome
- Sponsor
- International Brain Research Foundation
SARS Coronavirus (SARS-CoV-2) Infection
A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City; COVID-19
This study is to gain critical knowledge to understand the factors influencing the outcome of a pandemic virus within the city of Basel.
- Trial name
- NCT04351503
- Testing
- Study A, Study B, Study C
- Where
- 6 sites in Switzerland
- Volunteers
- 126,586 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Malaria,Falciparum, Anemia in Children
Comparing Chemoprevention Drugs for School-based Malaria Control
This is an individually randomized, controlled, single blind three arm clinical trial of malaria chemoprevention strategies Arm 1: Intermittent preventive treatment with dihydroartemisinin-piperaquine (IPT-DP).
- Trial name
- NCT05980156
- Testing
- Dihydroartemisinin-Piperaquine, Chloroquine, Sulfadoxine pyrimethamine
- Where
- Malawi
- Volunteers
- 646 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
COVID19, Coronavirus
Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting
The study is a double-blind, randomised, placebo-controlled trial that will be conducted primarily in healthcare settings and other facilities directly involved in COVID-19 case management.
- Conditions
- COVID19, Coronavirus, Acute Respiratory Illnesses
- Trial name
- COPCOV (NCT04303507)
- Testing
- Chloroquine or Hydroxychloroquine
- Where
- 25 sites in Benin, Côte d’Ivoire and 8 more
- Volunteers
- 4,652 people, healthy volunteers welcome
- Sponsor
- University of Oxford